Home Featured Page 277

Featured

Latest

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could...

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State & Exploring Ibogaine’s Potential

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1)

Karina Bashir on Psychedelics, Islam, and Human Rights

Lobe Sciences Signs Definitive Agreement for Sale of Cowlitz Cannabis Assets...

PT232 – Dr. Ryan Westrum – Who We Are Without Medicine

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery...

Aion Therapeutic Announces Closing of Non-Brokered Private Placement

Bright Minds Biosciences Inc. Announces Marketed Public Offering

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

Religious Use of Psychedelics in the United States

The Farmer and The Cowman Should Be Friends: Why the Pharmaceutical...

The Problem and Paradox of Bad Trips, Part 2

1...276277278...293 Page 277 of 293

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice;...

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could...

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State & Exploring Ibogaine’s Potential

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1)

Karina Bashir on Psychedelics, Islam, and Human Rights

DMT Pricing Guide

Lobe Sciences Signs Definitive Agreement for Sale of Cowlitz Cannabis Assets...

PT232 – Dr. Ryan Westrum – Who We Are Without Medicine

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery...

Aion Therapeutic Announces Closing of Non-Brokered Private Placement

Bright Minds Biosciences Inc. Announces Marketed Public Offering

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

Religious Use of Psychedelics in the United States

The Farmer and The Cowman Should Be Friends: Why the Pharmaceutical...

The Problem and Paradox of Bad Trips, Part 2

EDITOR PICKS

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice;...

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY